December 11, 2023 at 12:30 PM
The highly awaited Breast Cancer trials with positive results - Paolo Tarantino
@ptarantinomd.bsky.social
@sabcs.bsky.social
oncodaily.com/blog/208123
#BreastOncology #Cancer #ESMO23 #FightAgainstCancer #OncoDaily #Oncology #SABCS23 #Medicine #Health
@ptarantinomd.bsky.social
@sabcs.bsky.social
oncodaily.com/blog/208123
#BreastOncology #Cancer #ESMO23 #FightAgainstCancer #OncoDaily #Oncology #SABCS23 #Medicine #Health
Paolo Tarantino: The highly awaited Breast Cancer trials with positive results - OncoDaily
Paolo Tarantino: The highly awaited Breast Cancer trials with positive results / breast oncology, cancer, ESMO23, fight against cancer, Global fight against
oncodaily.com
December 19, 2024 at 12:58 PM
The highly awaited Breast Cancer trials with positive results - Paolo Tarantino
@ptarantinomd.bsky.social
@sabcs.bsky.social
oncodaily.com/blog/208123
#BreastOncology #Cancer #ESMO23 #FightAgainstCancer #OncoDaily #Oncology #SABCS23 #Medicine #Health
@ptarantinomd.bsky.social
@sabcs.bsky.social
oncodaily.com/blog/208123
#BreastOncology #Cancer #ESMO23 #FightAgainstCancer #OncoDaily #Oncology #SABCS23 #Medicine #Health
One year ago, on a sunny afternoon before the last session of #SABCS23, I stood on this balcony chatting with patient and advocate Gwen Manchion, who was stolen by MBC in the interim. This is why we do what we do.
December 13, 2024 at 11:12 PM
One year ago, on a sunny afternoon before the last session of #SABCS23, I stood on this balcony chatting with patient and advocate Gwen Manchion, who was stolen by MBC in the interim. This is why we do what we do.
#SABCS23 late breaking abstract to FDA approval: #Inavolisib based off #INAVO120 we 🗣️ design, findings, and AEs/management w/ Dr. Komal Jhaveri!
Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast
#OncSky #MedSky #bcsm #BreastCancer #SABCS24
Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast
#OncSky #MedSky #bcsm #BreastCancer #SABCS24
November 25, 2024 at 3:14 PM
#SABCS23 late breaking abstract to FDA approval: #Inavolisib based off #INAVO120 we 🗣️ design, findings, and AEs/management w/ Dr. Komal Jhaveri!
Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast
#OncSky #MedSky #bcsm #BreastCancer #SABCS24
Full Discussion:
- Oncbrothers.com/inavo120
- Also on the “Oncology Brothers” podcast
#OncSky #MedSky #bcsm #BreastCancer #SABCS24
Following the results presented at #SABCS23, the PREFERABLE-EFFECT trial is now out in @JCO_ASCO
Exercise for patients with metastatic #breastcancer ⬆️quality of life, ⬇️costs, and is cost-effective🏋🏼♀️🏃🏼♀️➡️
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Exercise for patients with metastatic #breastcancer ⬆️quality of life, ⬇️costs, and is cost-effective🏋🏼♀️🏃🏼♀️➡️
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Supervised Exercise for Patients With Metastatic Breast Cancer: A Cost-Utility Analysis Alongside the PREFERABLE-EFFECT Randomized Controlled Trial
PURPOSETo evaluate the cost utility of a 9-month supervised exercise program for patients
with metastatic breast cancer (mBC), compared with control (usual care, supplemented
with general activity adv...
ascopubs.org
January 15, 2025 at 1:59 PM
Following the results presented at #SABCS23, the PREFERABLE-EFFECT trial is now out in @JCO_ASCO
Exercise for patients with metastatic #breastcancer ⬆️quality of life, ⬇️costs, and is cost-effective🏋🏼♀️🏃🏼♀️➡️
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Exercise for patients with metastatic #breastcancer ⬆️quality of life, ⬇️costs, and is cost-effective🏋🏼♀️🏃🏼♀️➡️
@oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
Anyone planning on #SABCS23 here next week?
Knowing there are many who left the formerly known as Tweet bird app and curious as to real-time conference sharing energy on this site.
Knowing there are many who left the formerly known as Tweet bird app and curious as to real-time conference sharing energy on this site.
November 30, 2023 at 11:22 PM
Anyone planning on #SABCS23 here next week?
Knowing there are many who left the formerly known as Tweet bird app and curious as to real-time conference sharing energy on this site.
Knowing there are many who left the formerly known as Tweet bird app and curious as to real-time conference sharing energy on this site.
Finally, and only approved a couple of weeks ago, is Capivasertib (Trucap), an AKT inhibitor, approved for those with mutations in the PIK3CA-AKT-MTOR pathway or loss of PTEN. PFS was better in those with these mutations, confirmed by blinded independent review. #SABCS23
November 17, 2024 at 1:52 AM
Finally, and only approved a couple of weeks ago, is Capivasertib (Trucap), an AKT inhibitor, approved for those with mutations in the PIK3CA-AKT-MTOR pathway or loss of PTEN. PFS was better in those with these mutations, confirmed by blinded independent review. #SABCS23
Germline mutation status of BRCA1/2 as biomarker: Higher pCR rates observed in mutations carriers in all arms. Mutation carriers and non-carriers benefitted most from weekly nab-paclitaxel.
Analysis from GeparX-trial presented at #SABCS23 #breastcancer
Analysis from GeparX-trial presented at #SABCS23 #breastcancer
December 6, 2023 at 6:12 PM
Germline mutation status of BRCA1/2 as biomarker: Higher pCR rates observed in mutations carriers in all arms. Mutation carriers and non-carriers benefitted most from weekly nab-paclitaxel.
Analysis from GeparX-trial presented at #SABCS23 #breastcancer
Analysis from GeparX-trial presented at #SABCS23 #breastcancer
😞 to be leaving #sabcs22 in hopes of beating a major ❄️ storm at home. Seeing #advocate, oncologist, & researcher friends recharged me. This is the ⭐️ breast cancer conference & while the science is incredible, I really come for the people 💙💚💗 🏨 for #sabcs23 already booked!
November 17, 2024 at 5:17 AM
Elacestrant, recently approved oral SERD, in EMERALD trial showed positive PFS - most pronounced in those with ESR1 mutation who demonstrated endocrine sensitivity by having a longer PFS on a CDK4/6 inhibitor. #SABCS23
November 17, 2024 at 2:18 AM
Elacestrant, recently approved oral SERD, in EMERALD trial showed positive PFS - most pronounced in those with ESR1 mutation who demonstrated endocrine sensitivity by having a longer PFS on a CDK4/6 inhibitor. #SABCS23
Combos with oral SERDs (and CERANs and the rest of the alphabet soup) are in the works. I’m excited about the possibility of these (super happy so far with my combo of investigational palazestrant (SERD and CERAN) with ribociclib) #SABCS23
November 17, 2024 at 2:18 AM
Combos with oral SERDs (and CERANs and the rest of the alphabet soup) are in the works. I’m excited about the possibility of these (super happy so far with my combo of investigational palazestrant (SERD and CERAN) with ribociclib) #SABCS23
First up TDXd aka Enhertu, a ADC approved for both HER2+ and HER2low MBC. Pretty sure it was approved in HER2low population about a year ago due to results from DESTINY-breast02 trial. #SABCS23
November 17, 2024 at 2:10 AM
First up TDXd aka Enhertu, a ADC approved for both HER2+ and HER2low MBC. Pretty sure it was approved in HER2low population about a year ago due to results from DESTINY-breast02 trial. #SABCS23
What do we need to think about in the progression after CDK4/6i? How about how long someone responded to a CDK4/6i? What about genetic and genomic mutations? And most important: patient goals and preferences! #SABCS23
November 17, 2024 at 2:09 AM
What do we need to think about in the progression after CDK4/6i? How about how long someone responded to a CDK4/6i? What about genetic and genomic mutations? And most important: patient goals and preferences! #SABCS23
And we shouldn’t forget about older drugs, like everolimus, where everolimus + fulvestrant was better than fulvestrant alone (again the whole monotherapy after progression on a combo issue). #SABCS23
November 17, 2024 at 2:09 AM
And we shouldn’t forget about older drugs, like everolimus, where everolimus + fulvestrant was better than fulvestrant alone (again the whole monotherapy after progression on a combo issue). #SABCS23
Some suggestions for our care teams, including that (gasp!) we have lives outside of cancer and simple things like scheduling visits/scans/etc should be done WITH us and not TO us. #SABCS23
November 17, 2024 at 2:09 AM
Some suggestions for our care teams, including that (gasp!) we have lives outside of cancer and simple things like scheduling visits/scans/etc should be done WITH us and not TO us. #SABCS23
Interstitial lung disease (pneumonias) and left heart dysfunction are the main, and most worrisome, side effects as these can ☠️ if unrecognized and untreated. Frequent chest CT scans in the first few mi the of therapy should be done to screen for ILD. #SABCS23
November 17, 2024 at 2:01 AM
Interstitial lung disease (pneumonias) and left heart dysfunction are the main, and most worrisome, side effects as these can ☠️ if unrecognized and untreated. Frequent chest CT scans in the first few mi the of therapy should be done to screen for ILD. #SABCS23
next upelacestrant, aka Orserdu, an oral SERD, for ER+, HER2- MBC with an ESR1 genomic mutation. Approval was based on EMERALD trial, where all patients had had prior endocrine therapy. #SABCS23
November 17, 2024 at 2:01 AM
next upelacestrant, aka Orserdu, an oral SERD, for ER+, HER2- MBC with an ESR1 genomic mutation. Approval was based on EMERALD trial, where all patients had had prior endocrine therapy. #SABCS23
While there was a benefit in those without ESR1mutation, the benefit was much greater in those with the mutation, hence approval in only those with mutant ESR1. Another reason is that in those w/o ESR1 there was higher withdrawal of consent, raising concerns about data. #SABCS23
November 17, 2024 at 2:01 AM
While there was a benefit in those without ESR1mutation, the benefit was much greater in those with the mutation, hence approval in only those with mutant ESR1. Another reason is that in those w/o ESR1 there was higher withdrawal of consent, raising concerns about data. #SABCS23
Nausea was a common side effect, which is not surprising considering it’s an oral drug. It can also increase cholesterol, so this needs to be monitored. #SABCS23
November 17, 2024 at 2:01 AM
Nausea was a common side effect, which is not surprising considering it’s an oral drug. It can also increase cholesterol, so this needs to be monitored. #SABCS23
Side effects are common with Capivasertib, significantly diarrhea and rash; there’s less impact on blood sugar than alpelisib. Still waiting on effective tx with minimal toxicities. Not holding my breath (although my current trial is good so far in terms of AEs!). #SABCS23
November 17, 2024 at 2:01 AM
Side effects are common with Capivasertib, significantly diarrhea and rash; there’s less impact on blood sugar than alpelisib. Still waiting on effective tx with minimal toxicities. Not holding my breath (although my current trial is good so far in terms of AEs!). #SABCS23